1 / 21

Peripartum Cardiomyopathy

Peripartum Cardiomyopathy. Niloufar Samiei, MD, FACC Associate Professor of Cardiology Rajie Cardiovascular Medical and Research Center President of Iranian Society of Echocardiography. Definition

bviola
Télécharger la présentation

Peripartum Cardiomyopathy

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. Peripartum Cardiomyopathy Niloufar Samiei, MD, FACC Associate Professor of Cardiology Rajie Cardiovascular Medical and Research Center President of Iranian Society of Echocardiography

  2. Definition • Heart Failure Association of the European Society of Cardiology Working Group on PPCM 2010 • An idiopathic cardiomyopathy that presents with heart failure secondary to left ventricular systolic dysfunction toward the end of pregnancy or in the months after delivery, in the absence of any other cause of heart failure. PPCM is a diagnosis of exclusion. Although the left ventricle may not be dilated, the ejection fraction is nearly always reduced below 45%

  3. Why It Is Important • An important cause of pregnancy-related maternal mortality in previously healthy young women • The clinical course of this disease is highly unpredictable • Diagnosis of exclusion • A sizable minority of women with PPCM develop symptoms of HF earlier than the last gestational month

  4. Incidence • The incidence of PPCM varies widely • Between 1 in 100 and 1 in 300 live births in Africa and Haiti • 1 in 3,000 live births in the United States • 1 in 6,000 live births in Japan • Recently, a trend for an increased incidence in the United States

  5. Risk Factors • Obesity • Personal history of cardiac disorders such as myocarditis • Use of certain medicines • Smoking • Alcolism • Multiple pregnancies • Older age of gestation • Pre-eclampsia, hypertensive disorders • African American descent • Poor nourishment • Familial and genetic predisposition • Maternal cocaine abuse • Long-term (>4 weeks) oral tocolytic therapy with beta adrenergic agonists such as Terbutaline

  6. Etiopathology • Still unclear • A low selenium level, viral infections • Stress-activated cytokines • Inflammation • Autoimmune reactions • May be a vascular disease triggered by the hormonal changes of late pregnancy

  7. Proteolytic cleavage of the nursing hormone prolactin • A vasotoxic, proapoptotic, proinflammatory 16- kDa prolactin fragment • Up-regulation of microribonucleic acid-146a, and causing impairment of both endothelial function and cardiomyocyte metabolism • sFLT-1, another antiangiogenic factor released from the placenta during later stages of pregnancy • Prominent inhibition of proangiogenic factors • A significantly elevated serum level of sFLT-1 associated with pre-eclampsia and also in women with PPCM • The concept of a shared pathogenesis of the 2 diseases

  8. A vascular disease triggered by the hormonal changes of late pregnancy • Integration of oxidative stress, angiogenic imbalance, and impaired cardiomyocyte protection

  9. Clinical Presentation • Normal pregnancy is often associated with signs and symptoms that can overlap with those of HF • The diagnosis of PPCM can be easily missed in the absence of awareness of this disease and unfortunately is often delayed • Physical examination usually reveals the typical findings of HF

  10. Electrocardiogram : nonspecific ST-segment and T-wave changes • Chest radiograph : pulmonary congestion/edema and, in some cases, pleural effusion • TTE: LV systolic dysfunction (left ventricular ejection fraction (LVEF<45%) in the presence of a dilated or normalsized LV • CMR :still not well established, might provide additional information on cardiac structure and remodeling • N-terminal pro– B-type natriuretic peptide : significantly elevated in symptomatic patients with PPCM • Troponin T: is less sensitive and may be only slightly elevated in acute PPCM, but predict persistent LV dysfunction

  11. Prognosis • More favorable in PPCM than in other types of cardiomyopathies • Mortality or severe and lasting morbidity, including pulmonary edema, cardiogenic shock, fatal arrhythmias, and thromboembolic events • Mortality rate ranging from 0% to 19%, • In South Africa and Haiti of up to 30% • Older age, multiparity, severe impairment of LV function, AA ethnicity, and delayed diagnosis • In a recent prospective IPAC :the reported 1-year mortality was only 4% • Timely diagnosis and treatment can significantly improve outcomes

  12. LV function recovery • Earlier reports: recovery of LV function (LVEF 50%) occurs in ~50% of cases in the United States • A recent IPAC prospective study :72% • A significantly lower rate of LV recovery (35%) in another one • IPAC found that ~60% of AA women with PPCM achieved complete LV recovery • Improvement of LVEF occurs within 6 months of diagnosis • Lower LVEF and larger left ventricular end-diastolic diameter (LVEDD) at diagnosis appear to be significant adverse predictors for recovery, in addition to AA descent • No women with LVEDD ≥60 mm and LVEF ≤30% had recovered fully at 1 year of follow-up • AA race and late PPCM presentation (>6 weeks postpartum) • BNP level above 1860 pg/mL • LGE on CMR

  13. Subsequent pregnancies • A decrease in the LVEF >20% during subsequent pregnancy (SSP) in 21% of women with PPCM with LV recovery (LVEF ≥0.50), compared with 44% of nonrecovered women • No deaths with SSPs in the recovered group, but mortality of 13% in those without LVEF recovery • Relapse in 67% of women with LVEF<45% and in 33% of those with LVEF 50% to 54%, but also in 17% of women with LVEF 55% • Normalization of LV function after PPCM does not guarantee an uncomplicated SSP

  14. Treatment • Standard treatment consists of guideline-recommended optimal therapy for HF, with attention to preventing side effects in the fetus • Sodium restriction for all patients, whereas loop diuretic for the symptomatic relief of significant peripheral edema or pulmonary congestion • Angiotensin-converting enzyme inhibitors (ACEIs) and angiotensin-receptor blockers (ARBs) are contraindicated • Nitrates and hydralazine can be a safe • Beta-blockers are indicated, the use of beta-1–selective betablockers is generally preferred, particularly metoprolol tartrate • Digoxin can be used during pregnancy • The use of spironolactone is not recommended during pregnancy antiandrogen effects feminization in male animals and endocrine dysfunction in both sexes • Anticoagulation seems to be of particular importance in patients with PPCM and LVEF<40% during pregnancy and for at least the first 8 weeks post-partum because of the hypercoagulable state but still contoversy

  15. Although mortality is mostly due to HF, sudden arrhythmic death is not uncommon • Wearable cardioverter-defibrillator during the first 6 months in women with PPCM with severely reduced LV function as a bridge to improvement of LVEF • Mechanical support, such as an LVAD used as a bridge to recovery or to heart transplantation in critically ill women with refractory HF

  16. Delivery • With regard to women who are diagnosed antepartum and remain in stable condition on appropriate therapy, close monitoring and continuation of pregnancy is possible with attention to appropriate timing and mode of delivery • In those with worsening LV function and symptoms of HF termination of pregnancy or early delivery is indicated, with possible clinical improvement in many cases • C.S versus VD should be discussed

  17. Breast Feeding • There is a paucity of data • Breastfeeding in 67% found better outcomes in these women compared with those who did not breastfeed • IPAC study, breastfeeding was not associated with lower rates of LV recovery • Generally, the concentration of metoprolol tartrate, enalapril, and captopril in the breast milk is very low • The active metabolite of spironolactone, is found in milk at clinically insignificant doses • Controversy • Women in clinically stable condition with PPCM should not be advised against breastfeeding (Elkayam) • Long-term follow-up

  18. Long-term Follow-up • In women experienced LV function recovery :a number of reported cases of spontaneous LV function deterioration • No clear answer as to when to stop the ACEIs and betablockers in recovered patients • Gradual discontinuation with frequent monitoring of LV function is reasonable in patients with complete recovery of LV systolic function (LVEF >55%) and normal LV size • Assessment of contractile function by stress echocardiogram may be advisable before discontinuation of medications

  19. Specific Therapeutic Concepts in PPCM Treatment • A small open-design study of the use of intravenous immune reported a beneficial effect, but results were not evaluated further in a controlled trial • Pentoxifylline, as an anti–tumor necrosis factor alpha treatment • Levosimendan in not able to show any differences in the resolution of HF • Prolactin inhibition with bromocriptine, early experience : promising results • Until trial data becomes available, the use of bromocriptine for this indication should be used on an individual basis

  20. Contraception • Since women with PPCM with persistent left ventricular (LV) dysfunction or LV ejection fraction (LVEF) ≤25 percent at diagnosis are at high risk of recurrent PPCM, avoiding future pregnancy in such patients • The patient or her partner undergo a sterilization procedure or the patient use a highly effective non-estrogen method of contraception, such as the etonorgestrol implant, an IUD, or Depot medroxyprogestrone acetate as a second line alternative

More Related